The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Neuroinflammation is a key player in Parkinson’s disease and a prime target for therapy
Open accessAbstract
Parkinson’s disease (PD) is a neurodegenerative movement disorder characterized by the progressive loss of dopaminergic neurons in the substantia nigra and depletion of dopamine in the striatum, which lead to pathological and clinical abnormalities. Increasing evidence has demonstrated that inflammation is the fundamental process contributing to neuron death in PD. Neuroinflammation, which is characterized by activated microglia and infiltrating T cells at sites of neuronal injury, is a prominent contributor to the pathogenesis of progressive PD. Microglia play a critical role in forming a self-propelling cycle leading to sustained chronic neuroinflammation and driving the progressive neurodegeneration in PD. This activation depends heavily on the respiratory burst within the microglia, which in turn regulates a number of downstream pro-inflammatory activities. On the other hand, the adaptive immune responses, most notably T cells, are now emerging as important components of the inflammatory response that contribute to the pathogenesis of PD. This review paper focus on the understanding of the inflammatory etiology of PD, as well as the molecular signaling involved in this inflammatory response, with the aim to provide more effective treatments to slow down or halt the progression of chronic inflammation-induced CNS disorders, such as PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polazzi, E., Mengoni, I., Caprini, M., Peña-Altamira, E., Kurtys, E., & Monti, B. (2013) · Neurosignals · doi:10.1159/000337115 · Cited by 8,994
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240 · cited 3×
“Development of parkinsonian syndrome in such individuals has been attributed to mutations in several recently identified genes, including parkin, Leucine-rich repeat kinase 2 (LRRK2), ásynuclein, PINK-1, or DJ-1 (Polymeropoulos et al. 1997; Sun et al. 2006; Bonifati et al. 2008; Weng et al. 2007; Abou-Sleiman et al. 2…”
Interleukin-10 and the Interleukin-10 Receptor
Moore, K. W., de Waal Malefyt, R., Coffman, R. L., & O'Garra, A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.683 · Cited by 6,737
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110
Self-citationMcGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration
Qin, L., Wu, X., Block, M. L., Liu, Y., Breese, G. R., Hong, J., Knapp, D. J., & Crews, F. T. (2007) · Glia · doi:10.1002/glia.20467 · Cited by 2,144 · cited 4×
“Since it is known that systemically injected LPS cannot readily reach the brain, further studies show that pro-inflammatory factors, such as TNFa underlie the mechanism of systemic LPS-induced DA neurotoxicity (Qin et al. 2007).”
InfluentialSelf-citationNeuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
Kebir, H., Kreymborg, K., Ifergan, I., Dodelet-Devillers, A., Cayrol, R., Bernard, M., Giuliani, F., Arbour, N., Becher, B., & Prat, A. (2007) · Nature Medicine · doi:10.1038/nm1651 · Cited by 1,759 · cited 1×
“Th17 cells also might contribute to neurotoxicity through the release of proinflammatory cytokine IL-17, and secretion of granzyme B, a cytolytic enzyme (Kebir et al. 2007).”
Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs
Olson, J. K., & Miller, S. D. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.3916 · Cited by 1,215
Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183 · cited 1×
“The use of microglia inhibitor such as minocycline has shown potential neuroprotection in PD models (Wu et al. 2002; Du et al. 2001).”
Brochard, V., Combadière, B., Prigent, A., Laouar, Y., Perrin, A., Beray-Berthat, V., Bonduelle, O., Alvarez-Fischer, D., Callebert, J., Launay, J.-M., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36470 · Cited by 1,172
How NF-κB is activated: the role of the IκB kinase (IKK) complex
Karin, M. (1999) · Oncogene · doi:10.1038/sj.onc.1203219 · Cited by 1,156
Liu, B., & Hong, J.-S. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.035048 · Cited by 1,095
Self-citationLehnardt, S., Massillon, L., Follett, P., Jensen, F. E., Ratan, R., Rosenberg, P. A., Volpe, J. J., & Vartanian, T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1432609100 · Cited by 1,052
Kim, W.-G., Mohney, R. P., Wilson, B., Jeohn, G.-H., Liu, B., & Hong, J.-S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-16-06309.2000 · Cited by 878
Self-citationMogi, M., Harada, M., Kondo, T., Riederer, P., Inagaki, H., Minami, M., & Nagatsu, T. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90508-8 · Cited by 855
Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression
Gao, H.-M., & Hong, J.-S. (2008) · Trends in Immunology · doi:10.1016/j.it.2008.05.002 · Cited by 821
Self-citationDu, Y., Ma, Z., Lin, S., Dodel, R. C., Gao, F., Bales, K. R., Triarhou, L. C., Chernet, E., Perry, K. W., Nelson, D. L. G., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251341998 · Cited by 789
Innate immunity: the missing link in neuroprotection and neurodegeneration?
Nguyen, M. D., Julien, J.-P., & Rivest, S. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn752 · Cited by 701
Hunot, S., Brugg, B., Ricard, D., Michel, P. P., Muriel, M.-P., Ruberg, M., Faucheux, B. A., Agid, Y., & Hirsch, E. C. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7531 · Cited by 678
Coxon, A., Rieu, P., Barkalow, F. J., Askari, S., Sharpe, A. H., von Andrian, U. H., Arnaout, M. A., & Mayadas, T. N. (1996) · Immunity · doi:10.1016/s1074-7613(00)80278-2 · Cited by 627
Qin, L., Liu, Y., Wang, T., Wei, S.-J., Block, M. L., Wilson, B., Liu, B., & Hong, J.-S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m307657200 · Cited by 574 · cited 3×
“Moreover, PHOX activity also regulates production of pro-inflammatory cytokines such as TNFα by microglia following LPS stimulation (Qin et al. 2004), indicating that PHOX not only mediates superoxide production, but also controls the levels of other pro-inflammatory neurotoxic factors produced by…”
Self-citationActivation and assembly of the NADPH oxidase: a structural perspective
GROEMPING, Y., & RITTINGER, K. (2005) · Biochemical Journal · doi:10.1042/bj20041835 · Cited by 561
Changes in cytokines and neurotrophins in Parkinson’s disease
Nagatsu, T., Mogi, M., Ichinose, H., & Togari, A. (2000) · Advances in Research on Neurodegeneration · doi:10.1007/978-3-7091-6301-6_19 · Cited by 510
Ghosh, A., Roy, A., Liu, X., Kordower, J. H., Mufson, E. J., Hartley, D. M., Ghosh, S., Mosley, R. L., Gendelman, H. E., & Pahan, K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704908104 · Cited by 438
Salamone, J. D., Correa, M., Mingote, S., & Weber, S. M. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.035063 · Cited by 433
Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson’s disease
Reynolds, A. D., Banerjee, R., Liu, J., Gendelman, H. E., & Lee Mosley, R. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0507296 · Cited by 420
Reynolds, A. D., Stone, D. K., Hutter, J. A. L., Benner, E. J., Mosley, R. L., & Gendelman, H. E. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901852 · Cited by 406
Cicchetti, F., Brownell, A. L., Williams, K., Chen, Y. I., Livni, E., & Isacson, O. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.01938.x · Cited by 406
McGeer, P. L., Schwab, C., Parent, A., & Doudet, D. (2003) · Annals of Neurology · doi:10.1002/ana.10728 · Cited by 400
Strle, K., Zhou, J.-H., Shen, W.-H., Broussard, S. R., Johnson, R. W., Freund, G. G., Dantzer, R., & Kelley, K. W. (2001) · Critical Reviews™ in Immunology · doi:10.1615/critrevimmunol.v21.i5.20 · Cited by 400
NF-κB and IKK as therapeutic targets in cancer
Kim, H. J., Hawke, N., & Baldwin, A. S. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401877 · Cited by 391
NF-κB Regulates Phagocytic NADPH Oxidase by Inducing the Expression of gp91
Anrather, J., Racchumi, G., & Iadecola, C. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m506172200 · Cited by 386
The role of pathogenic DJ‐1 mutations in Parkinson's disease
Abou‐Sleiman, P. M., Healy, D. G., Quinn, N., Lees, A. J., & Wood, N. W. (2003) · Annals of Neurology · doi:10.1002/ana.10675 · Cited by 383
Kurkowska-Jastrzębska, I., Wrońska, A., Kohutnicka, M., Członkowski, A., & Członkowska, A. (1999) · Experimental Neurology · doi:10.1006/exnr.1998.6993 · Cited by 379
Nitrated α–Synuclein Immunity Accelerates Degeneration of Nigral Dopaminergic Neurons
Benner, E. J., Banerjee, R., Reynolds, A. D., Sherman, S., Pisarev, V. M., Tsiperson, V., Nemachek, C., Ciborowski, P., Przedborski, S., Mosley, R. L., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001376 · Cited by 362
Liu, B., Du, L., & Hong, J.-S. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39275-4 · Cited by 347 · cited 1×
“The neuroprotective potency of morphine is also similar to opioid receptor antagonist naloxone (Liu et al. 2000a, b).”
Self-citationTherapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease
Benner, E. J., Mosley, R. L., Destache, C. J., Lewis, T. B., Jackson-Lewis, V., Gorantla, S., Nemachek, C., Green, S. R., Przedborski, S., & Gendelman, H. E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400569101 · Cited by 321
Gao, H.-M., Liu, B., Zhang, W., & Hong, J.-S. (2003) · The FASEB Journal · doi:10.1096/fj.03-0109fje · Cited by 306
Self-citationCzłonkowska, A., Kohutnicka, M., Kurkowska-Jastrzębska, I., & Członkowski, A. (1996) · Neurodegeneration · doi:10.1006/neur.1996.0020 · Cited by 279
Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys
Miklossy, J., Doudet, D. D., Schwab, C., Yu, S., McGeer, E. G., & McGeer, P. L. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2005.10.034 · Cited by 255
Nguyen, M. D., D'Aigle, T., Gowing, G., Julien, J.-P., & Rivest, S. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4786-03.2004 · Cited by 248
Castaño, A., Herrera, A. J., Cano, J., & Machado, A. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00799.x · Cited by 238
Transforming Growth Factor-β1 Increases Bad Phosphorylation and Protects Neurons Against Damage
Zhu, Y., Yang, G.-Y., Ahlemeyer, B., Pang, L., Che, X.-M., Culmsee, C., Klumpp, S., & Krieglstein, J. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-10-03898.2002 · Cited by 224
Prehn, J. H., Bindokas, V. P., Marcuccilli, C. J., Krajewski, S., Reed, J. C., & Miller, R. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.12599 · Cited by 222
Can the brain be protected through exercise? Lessons from an animal model of parkinsonism☆
Smith, A. D., & Zigmond, M. J. (2003) · Experimental Neurology · doi:10.1016/j.expneurol.2003.08.017 · Cited by 209
Pathology of Parkinson's Disease
(2006) · Understanding Parkinson's Disease · doi:10.5040/9798216029700.0007 · Cited by 206
Liu, Y., Qin, L., Li, G., Zhang, W., An, L., Liu, B., & Hong, J.-S. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.043166 · Cited by 205
Self-citationHenrich-Noack, P., Prehn, J. H. M., & Krieglstein, J. (1996) · Stroke · doi:10.1161/01.str.27.9.1609 · Cited by 202 · cited 1×
“In addition, recombinant TGFβ delivered intracerebrally or via virus vectors protects animals against brain injury induced by ischemic (Unsicker and Krieglstein 2002), excitotoxic (Ruocco et al. 1999), and oxidative stress (Henrich-Noack et al. 1996).”
Nitrated α-Synuclein-Induced Alterations in Microglial Immunity Are Regulated by CD4+ T Cell Subsets
Reynolds, A. D., Stone, D. K., Mosley, R. L., & Gendelman, H. E. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803982 · Cited by 197
Inflammation in Parkinson's disease.
McGeer, P. L., Yasojima, K., & McGeer, E. G. (2001) · PubMed · Cited by 197
Angelov, D. N., Waibel, S., Guntinas-Lichius, O., Lenzen, M., Neiss, W. F., Tomov, T. L., Yoles, E., Kipnis, J., Schori, H., Reuter, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530191100 · Cited by 193
Liu, B., Jiang, J.-W., Wilson, B. C., Du, L., Yang, S.-N., Wang, J.-Y., Wu, G.-C., Cao, X.-D., & Hong, J.-S. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38877-9 · Cited by 167
Self-citationSun, M., Latourelle, J. C., Wooten, G. F., Lew, M., Klein, C., Shill, H. A., Golbe, L. I., Mark, M. H., Racette, B. A., Perlmutter, J. S., et al. (2006) · Archives of Neurology · doi:10.1001/archneur.63.6.826 · Cited by 164
Zhang, W., Dallas, S., Zhang, D., Guo, J., Pang, H., Wilson, B., Miller, D. S., Chen, B., Zhang, W., McGeer, P. L., et al. (2007) · Glia · doi:10.1002/glia.20532 · Cited by 160
Self-citationLi, Q., Xu, Z., Zhang, W., Wilson, B. C., Hong, J., & Flood, P. M. (2007) · Journal of Neuroinflammation · doi:10.1186/1742-2094-4-23 · Cited by 157
Self-citationGauss, K. A., Nelson-Overton, L. K., Siemsen, D. W., Gao, Y., DeLeo, F. R., & Quinn, M. T. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.1206735 · Cited by 157
Innate and Adaptive Immunity for the Pathobiology of Parkinson's Disease
Stone, D. K., Reynolds, A. D., Mosley, R. L., & Gendelman, H. E. (2009) · Antioxidants and Redox Signaling · doi:10.1089/ars.2009.2460 · Cited by 151
Bartels, A. L., & Leenders, K. L. (2007) · Movement Disorders · doi:10.1002/mds.21552 · Cited by 140
Increased cerebrospinal fluid concentration of nitrite in Parkinsonʼs disease
Qureshi, G. A., Baig, S., Bednar, I., Södersten, P., Forsberg, G., & Sidén, Å. (1995) · Neuroreport · doi:10.1097/00001756-199508000-00013 · Cited by 135
Hu, X., Zhang, D., Pang, H., Caudle, W. M., Li, Y., Gao, H., Liu, Y., Li, Q., Wilson, B. C., Monte, D. A. D., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.7194 · Cited by 133
Self-citationIs the cause of Parkinson's disease environmental or hereditary? Evidence from twin studies.
Tanner, C. M. (2003) · PubMed · Cited by 131
Thomas, M. P., Chartrand, K., Reynolds, A. D., Vitvitsky, V., Banerjee, R. V., & Gendelman, H. E. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04315.x · Cited by 127
Ruocco, A., Nicole, O., Docagne, F., Ali, C., Chazalviel, L., Komesli, S., Yablonsky, F., Roussel, S., MacKenzie, E. T., Vivien, D., et al. (1999) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199912000-00008 · Cited by 126
Li, Q., Block, M. L., Wei, S., Lin, C., Reece, J. M., Pang, H., Wilson, B. C., Hong, J., & Flood, P. M. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.106351 · Cited by 110
Self-citationSairam, K., Saravanan, K. S., Banerjee, R., & Mohanakumar, K. P. (2003) · Brain Research · doi:10.1016/s0006-8993(02)04174-4 · Cited by 106
Pei, Z., Pang, H., Qian, L., Yang, S., Wang, T., Zhang, W., Wu, X., Dallas, S., Wilson, B., Reece, J. M., et al. (2007) · Glia · doi:10.1002/glia.20545 · Cited by 105 · cited 1×
“We recently reported that microglial MAC1 was indispensable for the enhanced neurotoxicity induced by LPS, α-synuclein, or MPTP in neuron-glia cultures (Pei et al. 2007; Hu et al. 2008; Zhang et al. 2007), and MAC1-deficient mice show more resistance to MPTP-induced DA neurotoxicity in vivo.”
Zhang, F., Li, Q., Flood, P. M., Shi, J., Hong, J., & Gao, H. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.165829 · Cited by 100
Self-citationTGF-ßS and Their Roles in the Regulation of Neuron Survival
Unsicker, K., & KRIEGLSTEIN, K. G. (2003) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-0123-7_13 · Cited by 92
Proteomic Studies of Nitrated Alpha-Synuclein Microglia Regulation by CD4+CD25+ T Cells
Reynolds, A. D., Stone, D. K., Mosley, R. L., & Gendelman, H. E. (2009) · Journal of Proteome Research · doi:10.1021/pr9001614 · Cited by 88
Li, Q., Tan, K. S., Wei, S., Wu, H., Xu, Z., Wilson, B. C., Lu, R.-B., Hong, J., & Flood, P. M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.2.1198 · Cited by 87
Self-citationJackson-Lewis, V. R., & Smeyne, R. J. (2005) · Neurotoxicity Research · doi:10.1007/bf03036449 · Cited by 85
Xing, B., Liu, M., & Bing, G. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2007.09.029 · Cited by 83
Human Interleukin-10 Gene Transfer Is Protective in a Rat Model of Parkinson's Disease
Johnston, L. C., Su, X., Maguire‐Zeiss, K. A., Horovitz, K., Ankoudinova, I., Guschin, D. Y., Hadaczek, P., Federoff, H. J., Bankiewicz, K. S., & Forsayeth, J. (2008) · Molecular Therapy · doi:10.1038/mt.2008.113 · Cited by 81
Zhang, W., Shin, E., Wang, T., Lee, P. H., Pang, H., Wie, M., Kim, W., Kim, S., Huang, W., Wang, Y., et al. (2006) · The FASEB Journal · doi:10.1096/fj.06-6006com · Cited by 76
Self-citationZhang, W., Qin, L., Wang, T., Wei, S., Gao, H., Liu, J., Wilson, B. C., Liu, B., Zhang, W., Kim, H., et al. (2004) · The FASEB Journal · doi:10.1096/fj.04-1586fje · Cited by 72
Self-citationFamilial Parkinson's disease. Alpha-synuclein and parkin.
Mizuno, Y., Hattori, N., Kitada, T., Matsumine, H., Mori, H., Shimura, H., Kubo, S., Kobayashi, H., Asakawa, S., Minoshima, S., et al. (2001) · PubMed · Cited by 72
LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8
Nichols, W. C., Elsaesser, V. E., Pankratz, N., Pauciulo, M. W., Marek, D. K., Halter, C. A., Rudolph, A., Shults, C. W., & Foroud, T. (2007) · Neurology · doi:10.1212/01.wnl.0000278115.50741.4e · Cited by 67
Effects of Enhanced Striatal Dopamine Turnover In Vivo on Glutathione Oxidation
Loeffler, D. A., DeMaggio, A. J., Juneau, P. L., Havaich, M. K., & LeWitt, P. A. (1994) · Clinical Neuropharmacology · doi:10.1097/00002826-199408000-00009 · Cited by 61
Bernardo, A., Ajmone‐Cat, M. A., Gasparini, L., Ongini, E., & Minghetti, L. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02932.x · Cited by 58
Li, Q., Gao, X., Pei, Z., Wu, X., Block, M. L., Wilson, B. C., Hong, J., & Flood, P. M. (2007) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(08)70023-3 · Cited by 58
Self-citation(2007) · doi:10.1016/j.neurobiolaging.2006.07.017 · Cited by 46
PINK1 mutation in Taiwanese early-onset parkinsonism
Weng, Y.-H., Chou, Y. W., Wu, W.-S., Lin, K., Chang, H., Yen, T., Chen, R., Wey, S., & Lu, C. (2007) · Journal of Neurology · doi:10.1007/s00415-007-0534-7 · Cited by 45
A common vaccine for fighting neurodegenerative disorders: recharging immunity for homeostasis
Schwartz, M., & Kipnis, J. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.06.010 · Cited by 34
Do pathogen exposure and innate immunity cause brain diseases?
Simard, A. R., & Rivest, S. (2005) · Neurological Research · doi:10.1179/016164105x49526 · Cited by 30
INFLAMMATION IN PARKINSON'S DISEASE
Benigno, A., Esposito, E., Crescimanno, G., & Di Giovanni, G. (2007) · Nova Science Publishers (Nova Science Publishers, Inc.) · Cited by 24
Morphinan Neuroprotection: New Insight into the Therapy of Neurodegeneration
Zhang, W., Hong, J., Kim, H., Zhang, W., & Block, M. L. (2004) · Critical Reviews in Neurobiology · doi:10.1615/critrevneurobiol.v16.i4.30 · Cited by 10
Self-citationLangston, J. W., Forno, L. S., Tetrud, J., Reeves, A. G., Kaplan, J. A., & Karluk, D. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199910)46:4 · Cited by 1
Cited by
The Role of Oxidative Stress in Parkinson's Disease
Dias, V., Junn, E., & Mouradian, M. M. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130230 · Cited by 1,845
Inflammation and white matter degeneration persist for years after a single traumatic brain injury
Johnson, V. E., Stewart, J. E., Begbie, F. D., Trojanowski, J. Q., Smith, D. H., & Stewart, W. (2013) · Brain · doi:10.1093/brain/aws322 · Cited by 1,045
Oxidative stress, mitochondrial dysfunction and neurodegenerative diseases; a mechanistic insight
Bhat, A. H., Dar, K. B., Anees, S., Zargar, M. A., Masood, A., Sofi, M. A., & Ganie, S. A. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.07.025 · Cited by 928
Role of Oxidative Stress in Parkinson's Disease
Hwang, O. (2013) · Experimental Neurobiology · doi:10.5607/en.2013.22.1.11 · Cited by 835
Interrelation of Oxidative Stress and Inflammation in Neurodegenerative Disease: Role of TNF
Fischer, R., & Maier, O. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/610813 · Cited by 731
Metadata
- Authors
- Qian, L., Flood, P. M., & Hong, J.-S.
- Venue
- Journal of Neural Transmission
- Published
- 2010-06-23
- Volume
- 117
- Issue
- 8
- Pages
- 971-979
- ISSN
- 0300-9564 (ISSN-L)
- 1435-1463
- OpenAlex
- W2072942101
- Cited by
- 287
- References
- 89
- FWCI
- 14.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.